These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 4368450)

  • 1. Binding of heparin in vitro and in vivo to plasma proteins.
    Marciniak E
    J Lab Clin Med; 1974 Sep; 84(3):344-56. PubMed ID: 4368450
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the interaction of heparin with thrombin, antithrombin, and other plasma proteins.
    Longas MO; Ferguson WS; Finlay TH
    Arch Biochem Biophys; 1980 Apr; 200(2):505-602. PubMed ID: 7436418
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies of heparin affinity to antithrombin III and other proteins in vitro and in vivo.
    Takeda Y; Kobayashi N
    Thromb Haemost; 1977 Oct; 38(3):685-95. PubMed ID: 579514
    [No Abstract]   [Full Text] [Related]  

  • 4. Heparin cofactor and antithrombin.
    Abildgaard U
    Thromb Diath Haemorrh; 1975 Feb; 33(1):38-42. PubMed ID: 47193
    [No Abstract]   [Full Text] [Related]  

  • 5. A simple 2-step isolation procedure for human antithrombin II/III and its biological activity after insolubilization to agarose.
    Thaler E; Schmer G
    Trans Am Soc Artif Intern Organs; 1974; 20 B():516-20. PubMed ID: 4450303
    [No Abstract]   [Full Text] [Related]  

  • 6. Interaction of heparin with lipoproteins - role of the complex in the inactivation of thrombin and plasmin.
    Kecskés E; Büki KG; Bauer PI; Machovich R; Horváth I
    Thromb Haemost; 1983 Apr; 49(2):138-41. PubMed ID: 6223404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin.
    Young E; Wells P; Holloway S; Weitz J; Hirsh J
    Thromb Haemost; 1994 Mar; 71(3):300-4. PubMed ID: 8029793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of heparin on the activation of factor XI by fibrin-bound thrombin.
    von dem Borne PA; Meijers JC; Bouma BN
    Thromb Haemost; 1996 Sep; 76(3):347-53. PubMed ID: 8883269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-specific differences in binding of heparin to plasma proteins.
    Ignjatovic V; Straka E; Summerhayes R; Monagle P
    J Thromb Haemost; 2010 Jun; 8(6):1290-4. PubMed ID: 20218985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor.
    Yin ET; Wessler S; Stoll PJ
    J Biol Chem; 1971 Jun; 246(11):3712-9. PubMed ID: 4102937
    [No Abstract]   [Full Text] [Related]  

  • 13. RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins.
    Jeter ML; Ly LV; Fortenberry YM; Whinna HC; White RR; Rusconi CP; Sullenger BA; Church FC
    FEBS Lett; 2004 Jun; 568(1-3):10-4. PubMed ID: 15196911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin.
    Carlström AS; Liedén K; Björk I
    Thromb Res; 1977 Dec; 11(6):785-97. PubMed ID: 601749
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.
    Valentin S; Nordfang O; Bregengård C; Wildgoose P
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):713-20. PubMed ID: 8292720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein.
    Horie S; Hiraishi S; Hamuro T; Kamikubo Y; Matsuda J
    Thromb Haemost; 2002 Jan; 87(1):80-5. PubMed ID: 11848461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the reliability of the use of heparin immobilized on agarose for the study of the interactions among heparin, thrombin and antithrombin.
    Fish WW; Björk I
    Thromb Haemost; 1982 Aug; 48(1):84-6. PubMed ID: 7135347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proceedings: Adverse effect of heparin on thrombin inactivation.
    Marciniak E
    Thromb Diath Haemorrh; 1975 Sep; 34(1):365. PubMed ID: 1188832
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of heparin on structural and functional properties of low density lipoproteins.
    Krisko A; Piantanida I; Kveder M; Pifat G; Lee A; Greilberger J; Kipmen-Korgun D; Jürgens G
    Biophys Chem; 2006 Feb; 119(3):234-9. PubMed ID: 16233946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SR123781A, a synthetic heparin mimetic.
    Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
    Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.